Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years

Cellular Oncology

Volumn 29, Issue 1, 2007, Pages 25-35

  Janssen, Emiel A M ^a   Søiland, Håvard ^a   Skaland, Ivar ^a   Gudlaugson, Einar ^a   Kjellevold, Kjell H ^a   Nysted, Arne ^a   Søreide, Jon Arne ^a,b   Baak, Jan P A ^a,b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Akt pathway; Breast cancer; Cell proliferation; Mitotic Activity Index; PTEN

Indexed keywords

CELL CYCLE PROTEIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE;

EID: 34047207788     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. J.P.A. Baak, H. van Dop, P.H.J. Kurver and J. Hermans, The value of morphometry to classic prognosticators in breast cancer, Cancer 56 (1985), 374-382.
2. J.P.A. Baak, P.J. van Diest, A. Ariens, M.W. van Beek, S.M. Bellot, J. Fijnheer, L.H. van Gorp, W.S. Kwee, J. Los, H.C. Peterse et al., The multicenter morphometric mammary carcinoma project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands, Pathol. Res. Pract. 185 (1989), 664-670.
3. J.P. Baak, P.J. van Diest, F.J. Voorhorst, E. van der Wall, L.V. Beex, J.B. Vermorken and E.A. Janssen, Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years, J. Clin. Oncol. 23 (2005), 5993-6001.
4. E. Bergers, P.J. van Diest and J.P.A. Baak, Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical and pathologic variables. MMMCP Collaborative Group, Cancer 77 (1996), 2258-2266.
5. E. Bergers, P.J. van Diest and J.P.A. Baak, Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1301 breast cancer patients: Results from the Multicenter Morphometric Mammary Carcinoma Project, Int. J. Cancer 74 (1997), 260-269.
6. J.-H. Chung and C. Eng, Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis, Cancer Res. 65 (2005), 8096-8100.
7. M.G. Daidone and R. Silvestrini, Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer, J. Natl. Cancer Inst. Monogr. 30 (2001), 27-35.
8. P.L. Depowski, S.I. Rosenthal and J.S. Ross, Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer, Mod. Pathol. 14 (2001), 672-676.
9. P.J. van Diest, J.P.A. Baak, P. Matze-Cok, E.C. Wisse-Brekelmans, C.M. van Galen, P.H. Kurver, S.M. Bellot, J. Fijnheer, L.H. van Gorp and W.S. Kwee, Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project, Hum. Pathol. 23 (1992), 603-607.
10. P.J. van Diest, E. van der Wall and J.P. Baak, Prognostic value of proliferation in invasive breast cancer: a review, J. Clin. Pathol. 57 (2004), 675-681.
11. European Commission Group on Breast Screening Pathology: Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas, Virchows Arch. 434 (1999), 3-10.
12. I.O. Ellis, S.J. Schnitt, X. Sastre-Garau et al., Invasive breast carcinoma, in: Pathology and Genetics of Tumors of the Breast and Female Genital Tract Organs, F.A. Tavassoli and P. Devilee, ed., IARC Press, Lyon, 2003, pp. 18-19.
13. C.W. Elston and I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathol. 19 (1991), 403-410.
14. D. Freihoff, A. Kempe, B. Beste et al., Exclusion of a major role for the PTEN tumor-suppressor gene in breast carcinomas, Br. J. Cancer 79 (1999), 754-758.
15. A. Goldhirsch, J.H. Glick, R.D. Gelber, A.S. Coates, B. Thurlimann and H.J. Senn, Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005, Ann. Oncol. 16 (2005), 1569-1583.
16. L.A. de Graffenried, L. Fulcher, W.E. Friedrichs, V. Grunwald, R.B. Ray and M. Hidalgo, Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway, Ann. Oncol. 15 (2004), 1510-1516.
17. E.A.M. Janssen, J.P.A. Baak, M.A. Guervós, P.J. van Diest, M. Jiwa and M.A. Hermsen, In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumor diameter, and oestrogen receptor, J. Pathol. 201 (2003), 555-561.
18. E.A.M. Janssen, P.J. van Diest, H. Søiland, E. Gudlaugson, A. Nysted, F.J. Voorhorst, J.A. Søreide and J.P.A. Baak, Success predictors of adjuvant chemotherapy node-negative breast cancer patients under 55 years, Cell. Oncol. 28(5-6) (2006), 295-303.
19. S. Jauliac, C. Lopez-Rodriguez, L.M. Shaw, L.F. Brown, A. Rao and A. Toker, The role of NFAT transcription factors in integrin-mediated carcinoma invasion, Nat. Cell. Biol. 4 (2002), 540-544.
20. T. Kirkegaard, C.J. Witton, L.M. McGlynn, S.M. Tovey, B. Dunne, A. Lyon and J.M. Bartlett, AKT activation predicts outcome in breast cancer patients treated with tamoxifen, J. Pathol. 207 (2005), 139-146.
21. H.A. Lehr, D.A. Hansen, S. Kussick, M. Li, H. Hwang, F. Krummenauer, S. Trouet and A.M. Gown, Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count, Hum. Pathol. 30 (1999), 1314-1320.
22. H.-J. Lin, F.-C. Hsieh, H. Song and J. Lin, Elevated phosphorylation and activation of PDK-I/AKT pathway in human breast cancer, Br. J. Cancer 93 (2005), 1372-1381.
23. J.J. Michels, F. Duigou and J. Marnay, Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity, Breast Cancer Res. Treat. 62 (2000), 117-126.
24. A.R. Panigrahi, S.E. Pinder, S.Y. Chan, E.C. Paish, J.F. Robertson and I.O. Ellis, The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome, J. Pathol. 204 (2004), 93-100.
25. B. Salh, A. Marotta, R. Wagey, M. Sayed and S. Pelech, Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer, Int. J. Cancer 98 (2002), 148-154.
26. R. Silvestrini, M.G. Daidone and G. Di Fronzo, Prognostic implication of labelling index versus oestrogen receptors and tumor size in node-negative breast cancer, Breast Cancer Res. Treat. 7 (1986), 161-169.
27. H. Sigurdsson, B. Baldetorp, A. Borg, M. Dalberg, M. Ferno, D. Killander and H. Olsson, Indicators of prognosis in nodenegative breast cancer, N. Engl. J. Med. 322 (1990), 1045-1053.
28. A. Volpi, F. Bacci, A. Paradiso, L. Saragoni, E. Scarpi, M. Ricci, M. Aldi, S. Bianchi, P. Muretto, F. Nuzzo, G. Simone, A. Mangia, F. Schittulli and D. Amadori, Prognostic relevance of histological grade and its components in nodenegative breast cancer patients, Mod. Pathol. 17 (2004), 1038-1044.
29. World Health Organization, Histologic Typing of Breast Tumors, 2nd edn, World Health Organization, Geneva, 1981.
30. M. Yoeli-Lerner, G.K. Yiu, I. Rabinovitz, P. Erhardt, S. Jauliac and A. Toker, Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT, Mol. Cell. 20 (2005), 539-550.